锦华新材主要从事酮肟系列精细化学品的研发、生产和销售，主要产品包括硅烷交联剂、羟胺盐、甲氧胺盐酸盐、乙醛肟等。 中国经济网北京9月25日讯 今日，浙江锦华新材料股份有限公司（证券简称：锦华新材，证券代码：920015.BJ）在北交所上市。该股开盘报39.00 元，截至收盘报42.29元，涨幅133.00%，成交额11.32亿元，振幅71.46%，换手率91.23%，总市值55.26亿元。 本次发行前，巨化集团有限公司（以下简称"巨化集团"）直接持有公司80,837,240股股份，持股比例为82.49%，为公司控股股东。浙江省国资委直接 持有公司控股股东巨化集团76.49%股份，通过杭州钢铁集团有限公司间接持有巨化集团13.51%股权，共计持有巨化集团90.00%股权。公司的实际控制人 为浙江省国资委。 本次发行后，巨化集团持有公司的股份数量不变，为80,837,240股，占本次发行前公司总股本的82.49%，占本次发行后超额配售选择权行使前公司总 股本的61.87%，占本次发行后超额配售选择权全额行使后公司总股本的59.63%。报告期内及本次发行前后，公司控股股东、实际控制人未发生变动。 锦华新材于2025年 ...

北交所新股N锦华（920015）今日上市，开盘上涨114.88%，截至上午收盘涨幅扩大至147.99%，半日成 交量2409.42万股，成交额9.50亿元，换手率77.64%。 公司本次公开发行数量为3266.67万股，发行价格为18.15元，发行市盈率11.52倍，网上发行量为2613.33 万股。根据超额配售选择权机制，浙商证券已向网上投资者超额配售490.00万股，占初始发行股份数量 的15.00%，同时网上发行数量扩大至3103.33万股。本次发行战略配售股份合计653.33万股，占初始发 行规模的20.00%。 本次网上发行有效申购数量4689736.69万股，有效申购倍数为1511.19倍，有效申购 户数为52.49万户，网上获配比例为0.07%。（数据宝） （文章来源：证券时报网） 证券时报·数据宝统计显示，公司主要从事酮肟系列精细化学品的研发、生产和销售。 2022年、2023年、2024年公司净利润分别为7959.22万元、1.73亿元、2.11亿元。 ...

N锦华（920015）今日在北交所上市，开盘价39.00元，上涨114.88%。 公司主要从事酮肟系列精细化学品的研发、生产和销售。公司上市申请获北交所受理日期为2024年6月 21日，从受理到今日上市，累计用了461天。 证券时报·数据宝统计显示，公司本次公开发行数量为3266.67万股，发行价格为18.15元，发行市盈率 11.52倍，网上发行量为2613.33万股。根据超额配售选择权机制，浙商证券已向网上投资者超额配售 490.00万股，占初始发行股份数量的15.00%，同时网上发行数量扩大至3103.33万股。本次发行战略配 售股份合计653.33万股，占初始发行规模的20.00%。 本次网上发行有效申购数量4689736.69万股，有效 申购倍数为1511.19倍，有效申购户数为52.49万户，网上获配比例为0.07%。 2022年—2024年公司净利润分别为7959.22万元、1.73亿元、2.11亿元。（数据宝） 近期北交所上市新股首日开盘涨跌幅 | 代码 | 简称 | 上市日期 | 发行价 | 网上申购获配比例 | 上市首日开盘价 | 上市首日开盘涨跌幅 | | --- | --- | --- ...

Core Viewpoint - The recent listings of Jianfa Zhixin, United Power, and Jinhua New Materials on the stock exchanges highlight the growth and investment opportunities in the medical device and new energy sectors in China [1][2]. Group 1: Jianfa Zhixin - Jianfa Zhixin is a national high-value medical device distributor, primarily engaged in direct sales and distribution, providing centralized operation services for medical consumables to hospitals [1]. - The company has a market capitalization of 2.97 billion yuan, with an issuance price of 7.05 yuan per share and a P/E ratio of 13.29, significantly lower than the industry average of 25.73 [2]. - In 2024, Jianfa Zhixin's revenue is projected to be divided into three segments: direct sales (11.03 billion yuan, 61.69%), distribution (6.74 billion yuan, 37.68%), and services (112 million yuan, 0.63%) [4]. - The company plans to invest 1.4 billion yuan in information system upgrades, 1.04 billion yuan in centralized operation services, and 2.4 billion yuan to supplement working capital [3]. Group 2: United Power - United Power, spun off from the industrial automation giant Inovance Technology, specializes in new energy vehicle power systems, including electric drive and power supply systems [6][7]. - The company is a leader in the new energy vehicle power system sector, providing solutions to over 40 vehicle manufacturers and participating in the entire lifecycle of vehicle design and production [7]. - United Power's accounts receivable have increased significantly, with values of 1.85 billion yuan, 3.61 billion yuan, and 5.68 billion yuan from 2022 to 2024, representing 20.37%, 29.38%, and 31.45% of total assets respectively [8]. Group 3: Jinhua New Materials - Jinhua New Materials focuses on the research, production, and sales of ketoxime series fine chemicals, being a leader in the domestic silane crosslinking agent market with market shares of 27.85%, 31.60%, and 38.16% from 2022 to 2024 [9]. - The company's products are essential for various industries, including construction, energy, electronics, and new energy vehicles [9]. - Jinhua New Materials has received multiple national honors and has participated in the formulation of several industry standards [9].

9月25日，创业板的建发致新（301584.SZ）和联合动力（301656.SZ）、北交所的锦华新材 （920015.BJ）上市。 建发致新是全国性的高值医疗器械流通商，主要从事医疗器械直销及分销业务，并为终端医院提供医用 耗材集约化运营（SPD）等服务。在医疗器械产业链中，建发致新主要承担医疗器械的流通职能，是串 联生产厂商、经销商、终端医疗机构的枢纽，在产业链中起到承上启下的重要作用。 招股书显示，建发致新为国企供应链巨头厦门建发集团旗下的医疗供应链企业。从股权结构来看，建发 医疗持有建发致新股份的比例为51.02%，而建发集团直接及间接持有建发医疗100.00%股权，厦门市国 资委持有建发集团100%股权，因此，厦门市国资委间接持有建发致新51.02%股份，为公司实际控制 人。 2024年，建发致新收入按业务类别可分为三大板块，分别为直销业务(110.32亿元，61.69%）、分销业 务（67.38亿元，37.68%）、服务业务（1.12亿元，0.63%）；目前，公司以直销业务为主、收入占比在 60%以上。 在直销方面，建发致新为31个省、自治区、直辖市超过3300家医疗机构提供上万种规格型号产品；主要 ...

Core Viewpoint - Huasoft Technology (002453) has experienced a significant increase in stock price due to heightened market interest in its involvement with the "photoresist" concept, despite the company's current revenue from related products being minimal [2]. Group 1: Company Overview - Huasoft Technology's main business focuses on the research, production, and sales of fine chemical products, including paper chemicals, pharmaceutical/agricultural intermediates, fluorescent whitening agents, and electronic chemicals [2]. - The revenue from electronic chemicals is projected to account for less than 6% of the company's total revenue in 2024 [2]. Group 2: Photoresist Business - The company has existing photo initiator products that are produced in small batches based on customer orders, with revenue from these products expected to contribute less than 2% to total revenue in 2024 [2]. - The impact of the photoresist business on the company's overall performance has been minimal for the past two years, and future sales are subject to significant uncertainty due to various influencing factors [2]. Group 3: Financial Performance - In the first half of 2025, Huasoft Technology's electronic chemicals business generated revenue of 15.88 million yuan, accounting for 9.3% of total revenue [3]. - For 2024, the electronic chemicals revenue is estimated at 30.11 million yuan, representing 5.84% of the company's total revenue [3].

Core Viewpoint - Huasoft Technology (002453) has experienced a significant increase in stock price due to heightened market interest in the "photoresist" concept, despite the company's limited revenue contribution from related products [1][2]. Group 1: Company Overview - Huasoft Technology's main business focuses on the research, production, and sales of fine chemical products, including paper chemicals, pharmaceutical/agricultural intermediates, fluorescent whitening agents, and electronic chemicals [1]. - The revenue from electronic chemicals is projected to account for less than 6% of the company's total revenue in 2024 [1]. Group 2: Photoresist Business - The company currently produces photo initiator products in small batches based on customer orders, with revenue from these products expected to contribute less than 2% to total revenue in 2024 [1]. - The impact of the photoresist business on the company's overall performance has been minimal for the past two years, and future sales are subject to significant uncertainty due to various influencing factors [1]. Group 3: Market Response - On September 24, Huasoft Technology's stock price rose by 10%, reaching a new high since January 2024, with over 330,000 shares traded at the close [1]. - The company's electronic chemicals business reported revenue of 15.88 million yuan in the first half of 2025, accounting for 9.3% of total revenue, while the 2024 revenue was 30.11 million yuan, representing 5.84% of total revenue [2].

Core Viewpoint - Huasoft Technology (002453) has experienced a significant stock price increase, attributed to heightened market interest in its involvement with the "photoresist" concept, despite the company's limited revenue contribution from this segment [1][2]. Group 1: Company Overview - Huasoft Technology's main business focuses on the research, production, and sales of fine chemical products, including paper chemicals, pharmaceutical/agricultural intermediates, fluorescent whitening agents, and electronic chemicals [1]. - The electronic chemicals segment is projected to contribute less than 6% to the company's total revenue in 2024 [1]. - The company's existing photoresist products, specifically photoinitiators, are produced in small batches based on customer orders, with revenue from this segment expected to be less than 2% of total revenue in 2024 [1]. Group 2: Market Performance - On September 24, Huasoft Technology's stock price rose by 10%, reaching a new high since January 2024, with over 330,000 shares traded by the end of the day [2]. - As of June 30, 2023, Huasoft Technology had approximately 44,600 shareholders [2]. Group 3: Product Details - Huasoft Technology's electronic chemicals include ML-8, which is a key raw material for coatings used in displays for mobile phones, computers, and televisions, enhancing performance while reducing energy consumption [2]. - The company's electronic chemicals generated revenue of 15.88 million yuan in the first half of 2025, accounting for 9.3% of total revenue, while the projected revenue for 2024 is 30.11 million yuan, representing 5.84% of total revenue [2].

Core Viewpoint - Huasoft Technology (002453.SZ) has announced that its existing photoinitiator products are being produced and sold in small batches based on customer orders, with revenue from these products expected to account for less than 2% of total revenue in 2024, indicating a limited impact on the company's overall performance in the near term [1] Company Overview - Huasoft Technology's main business focuses on the research, development, production, and sales of fine chemical products, including paper chemicals, pharmaceutical/agricultural intermediates, fluorescent whitening agents, and electronic chemicals [1] - The electronic chemicals segment is projected to contribute less than 6% to the company's total revenue in 2024 [1] Revenue Impact - The revenue from the existing photoinitiator products is anticipated to be minimal, with an estimated contribution of less than 2% to total revenue in 2024, reflecting a consistent trend over the past two years where the impact on operational performance has been minor [1] - Future sales of the photoinitiator products are subject to significant uncertainty due to various influencing factors [1]

Group 1 - The company, Huasoft Technology (002453.SZ), has announced unusual fluctuations in its stock trading, noting increased market attention on the "photoresist" concept [1] - The company's main business involves the research, production, and sales of fine chemical products, including paper chemicals, pharmaceutical/agricultural intermediates, fluorescent whitening agents, and electronic chemicals [1] - Electronic chemicals are projected to account for less than 6% of the company's total revenue in 2024 [1] Group 2 - Regarding the photoresist substrate business, the company currently produces photoinitiator products in small batches based on customer orders [1] - Revenue from these photoinitiator products is expected to represent about 2% of the company's total revenue in 2024, indicating a minimal impact on the company's operating performance over the past two years [1] - Future sales of these products are subject to significant uncertainty due to various influencing factors [1]